Chirality In Drug Development: From Racemic Mixtures To Enantiopure Substances

Chirality plays a critical role in drug development, as enantiomers of the same molecule can behave very differently in biological systems despite sharing identical chemical properties. Historically, many chiral drugs were developed as racemic mixtures due to technical limitations in separation. Advances in synthesis and solid‑state science have shifted this approach toward enantiopure drug substances, offering better control over pharmacokinetics, efficacy, and safety. Several routes exist to obtain single enantiomers, including asymmetric synthesis, chromatographic separation, and crystallization‑based techniques. Chiral crystallization is particularly attractive in early development because it combines broad applicability with scalability and cost efficiency. Techniques such as diastereomeric salt formation, preferential crystallization of conglomerates, and deracemization methods can be tailored to the molecule’s chemistry and racemization behavior. High‑throughput screening and targeted solid‑state characterization help identify viable crystallization pathways early. Applying these strategies enables robust process development while reducing risk and complexity as chiral drug candidates advance toward clinical stages.